CoChat

Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial

Grey, Andrew, Bolland, Mark, Wong, Sumwai, Horne, Anne, Gamble, Greg, Reid, Ian R. · 2012 · The Journal of Clinical Endocrinology & Metabolism
Cited by 51

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The skeletal effects of annual treatment with doses of zoledronate under 4 mg have not been assessed. Objective: Our objective was to determine the skeletal effects of single doses of zoledronate of 5 mg or less. Design, Setting, and Participants: This was a double-blind, randomized, placebo-controlled trial over 1 yr at an academic research center in 180 postmenopausal women with osteopenia. Intervention: Intervention was a single baseline administration of iv zoledronate in doses of 1, 2.5, or 5 mg, or placebo. Main Outcome Measures: The primary endpoint was change in bone mineral density (BMD) at the lumbar spine. Secondary endpoints were change in BMD at the proximal femur and total body and changes in biochemical markers of bone turnover. Results: After 12 months, change in spine BMD was greater in each of the zoledronate groups than in the placebo group [mean (95% confidence interval) difference vs. placebo was 3.5% (2.2–4.8%) for 1 mg, 4.0% (2.7–5.3%) for 2.5 mg, and 3.6% (2.3–4.9%) for 5 mg zoledronate, P < 0.001 for each dose]. Change in BMD at the total hip was greater in each of the zoledronate groups than the placebo group [mean (95% confidence interval) difference vs. placebo was 2.7% (1.9–3.5%) for 1 mg, 3.6% (2.8–4.4%) for 2.5 mg, and 3.6% (2.8–4.4%) for 5 mg zoledronate, P < 0.001 for each dose]. Each of the bone turnover markers, β-C-terminal telopeptide of type I collagen and procollagen type I N-terminal propeptide, was lower by at least 40% in each of the zoledronate groups than the placebo group throughout the trial (P < 0.001 vs. placebo for each marker for each dose). There was evidence for a dose-dependent effect of zoledronate on each of the markers (P for trend <0.001). Conclusion: Annual administration of doses of iv zoledronate lower than 5 mg produces substantial antiresorptive effects. Trials assessing the antifracture efficacy of low doses of zoledronate are justified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2011-2081

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 20

  1. Grey, 2009, The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women., J Clin Endocrinol Metab, 94, 538, 10.1210/jc.2008-2241 · DOI · Paper page
  2. Grey, 2010, Prolonged anti-resorptive activity of zoledronate: a randomized controlled trial., J Bone Miner Res, 25, 2251, 10.1002/jbmr.103 · DOI
  3. McClung, 2009, Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial., Obstet Gynecol, 114, 999, 10.1097/AOG.0b013e3181bdce0a · DOI · Paper page
  4. Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density., N Engl J Med, 346, 653, 10.1056/NEJMoa011807 · DOI · Paper page
  5. Reid, 2010, Characterization of and risk factors for the acute-phase response after zoledronic acid., J Clin Endocrinol Metab, 95, 4380, 10.1210/jc.2010-0597 · DOI · Paper page
  6. Brown, 2002, The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis., Calcif Tissue Int, 71, 103, 10.1007/s00223-002-2011-8 · DOI · Paper page
  7. Schnitzer, 2000, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group., Aging (Milano), 12, 1
  8. Watson, 2006, Health spending rising faster than GDP in most rich countries., BMJ, 333, 60, 10.1136/bmj.333.7558.60-a · doi:10.1136/bmj.333.7558.60-a
  9. Odvina, 2005, Severely suppressed bone turnover: a potential complication of alendronate therapy., J Clin Endocrinol Metab, 90, 1294, 10.1210/jc.2004-0952 · DOI · Paper page
  10. Lenart, 2008, Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate., N Engl J Med, 358, 1304, 10.1056/NEJMc0707493 · DOI · Paper page
  11. Kwek, 2008, An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy., Injury, 39, 224, 10.1016/j.injury.2007.08.036 · DOI · Paper page
  12. Shane, 2006, Osteonecrosis of the jaw: more research needed., J Bone Miner Res, 21, 1503, 10.1359/jbmr.060712 · DOI
  13. Heckbert, 2008, Use of alendronate and risk of incident atrial fibrillation in women., Arch Intern Med, 168, 826, 10.1001/archinte.168.8.826 · DOI · Paper page
  14. Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group., Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 · DOI · Paper page
  15. Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. [see comment]., N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 · DOI · Paper page
  16. Sebba, 2004, Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis., Curr Med Res Opin, 20, 2031, 10.1185/030079904X16768 · DOI
  17. Orwoll, 2010, Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study., J Bone Miner Res, 25, 2239, 10.1002/jbmr.119 · DOI · Paper page
  18. Rosen, 2010, Placebo-controlled trials in osteoporosis: proceeding with caution., N Engl J Med, 363, 1365, 10.1056/NEJMsb1002227 · doi:10.1056/nejmsb1002227
  19. Luckey, 2003, Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis., Obstet Gynecol, 101, 711
  20. Glover, 2009, Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States., J Bone Miner Res, 24, 389, 10.1359/jbmr.080703 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., & Reid, I. R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-01-01
Volume
97
Issue
1
Pages
286-292
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2036909315
Cited by
51
References
7
FWCI
3.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1210/jc.2011-2081
The paper
Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., & Reid, I. R. (2012). Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-2081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.